Serum metabolomic-lipidomic signatures track long-term neurological performance in multiple sclerosis.

ABSTRACT: Metabolomics incorporates information from multiple biological systems and is recognized as an emerging tool for identifying novel multiple sclerosis (MS) biomarkers. While prior studies have linked metabolic alterations to the disease severity in people with MS (pwMS), a longitudinal approach enables a significant advantage in studying this relationship over disease progression. Therefore, this study aims to identify metabolomic signatures associated with longitudinal outcomes in pwMS. We performed a multi-site study, profiling the serum metabolome (Biocrates Inc.) from participants for the MS Partners Advancing Technology and Health Solutions (MS PATHS) network. Outcomes, including 25-foot walking speed, manual dexterity, and processing speed, were quantified using the iPad®-based Multip

SUBMITTER: Noroozi R 

PROVIDER: S-EPMC12727765 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature